Netramark signs contract with AlgoTherapeutix

Executive Summary

• Netramark Holdings Inc. has entered into an agreement with clinical-stage biotechnology company AlgoTherapeutix SAS to enhance the clinical trial design for its ATX01 program.
• Netramark will deploy its NetraAI platform to analyze patient-level data from AlgoTx's ATX01 program, aiming to identify responder personas and deliver enrichment strategies to optimize future trials.
• The collaboration involves developing customized AI models and interactive tools to generate validated, explainable, and regulator-ready insights, with the goal of reducing placebo response and accelerating development timelines.

Key Details

• Parties Involved: Netramark Holdings Inc. (provider of NetraAI platform) and AlgoTherapeutix SAS (developer of ATX01 for chemotherapy-induced peripheral neuropathy).
• Scope of Agreement: Netramark will use its NetraAI technology to analyze patient-level data from the ATX01 program.
• Technical Objectives:
  • Deep exploration of drug and placebo response variables.
  • Identification of responder personas.
  • Delivery of enrichment strategies to inform the design of future ATX01 trials.
  • Development of customized AI models and interactive tools allowing the AlgoTx team to test hypotheses and vary clinical significance thresholds.
• Strategic Goals:
  • Reduce placebo response rates.
  • Improve signal detection.
  • Enrich trial populations with the most responsive patients.
  • Generate validated, explainable, and regulator-ready insights to optimize future studies.
  • Accelerate development timelines for non-opioid CIPN solutions.

Notable Quotes

• Josh Spiegel, President of Netramark: "AlgoTx is a leader in bringing innovation to complex pain treatments... Their decision to partner with us reflects the growing recognition that explainable, precision AI can unlock value from clinical data sets that conventional approaches overlook."
• Stephane Thiroloix, Founder and Chairman of the Board of AlgoTx: "This agreement reflects our commitment to applying best-in-class innovation at every stage of our pipeline to ensure we bring transformative therapies to patients as efficiently as possible."